The tumour mutational burden has been suggested to be related to the objective response rate to PD-1 inhibitors, and pancreatic cancer with a low number of genomic mutations is generally resistant to PD-1 or PD-L1 inhibitors. The gene discussed is PDCD1; the disease is pancreatic neoplasm.